The 36-month beta value for IGMS is at 0.48. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for IGMS is 16.72M, and currently, shorts hold a 4.31% of that float. The average trading volume for IGMS on July 01, 2025 was 212.80K shares.
IGMS) stock’s latest price update
IGM Biosciences Inc (NASDAQ: IGMS)’s stock price has increased by 19.64 compared to its previous closing price of 1.12. However, the company has seen a 13.56% increase in its stock price over the last five trading sessions. globenewswire.com reported 2025-07-01 that MOUNTAIN VIEW, Calif., July 01, 2025 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company that has focused on developing engineered IgM-based therapeutic antibodies, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with Concentra Biosciences, LLC (“Concentra”), whereby Concentra will acquire IGM Biosciences for $1.247 in cash per share of IGM Biosciences common stock (“Common Stock”), plus one non-tradeable contingent value right (“CVR”), which represents the right to receive: (i) 100% of the closing net cash of IGM Biosciences in excess of $82.0 million; and (ii) 80% of any net proceeds received within one year following closing from any disposition of certain of IGM Biosciences’ product candidates and intellectual property that occurs within one year following closing, each pursuant to a contingent value rights agreement (the “CVR Agreement”).
IGMS’s Market Performance
IGMS’s stock has risen by 13.56% in the past week, with a monthly rise of 5.51% and a quarterly rise of 16.52%. The volatility ratio for the week is 8.48% while the volatility levels for the last 30 days are 6.78% for IGM Biosciences Inc The simple moving average for the last 20 days is 9.57% for IGMS stock, with a simple moving average of -76.80% for the last 200 days.
Analysts’ Opinion of IGMS
Many brokerage firms have already submitted their reports for IGMS stocks, with Stifel repeating the rating for IGMS by listing it as a “Hold.” The predicted price for IGMS in the upcoming period, according to Stifel is $2.50 based on the research report published on January 10, 2025 of the current year 2025.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see IGMS reach a price target of $1.50, previously predicting the price at $20. The rating they have provided for IGMS stocks is “Sector Perform” according to the report published on January 10th, 2025.
Morgan Stanley gave a rating of “Underweight” to IGMS, setting the target price at $2 in the report published on January 10th of the current year.
IGMS Trading at 7.93% from the 50-Day Moving Average
After a stumble in the market that brought IGMS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -94.04% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IGMS starting from Weber Steven, who sale 486 shares at the price of $1.20 back on Jun 16 ’25. After this action, Weber Steven now owns 26,530 shares of IGM Biosciences Inc, valued at $583 using the latest closing price.
Tahir Misbah, the CHIEF FINANCIAL OFFICER of IGM Biosciences Inc, sale 1,522 shares at $1.20 during a trade that took place back on Jun 16 ’25, which means that Tahir Misbah is holding 178,802 shares at $1,825 based on the most recent closing price.
Stock Fundamentals for IGMS
Current profitability levels for the company are sitting at:
- -78.14 for the present operating margin
- -0.73 for the gross margin
The net margin for IGM Biosciences Inc stands at -74.18. The total capital return value is set at -1.17. Equity return is now at value -245.59, with -68.22 for asset returns.
Based on IGM Biosciences Inc (IGMS), the company’s capital structure generated 0.98 points at debt to capital in total, while cash flow to debt ratio is standing at -3.26.
Currently, EBITDA for the company is -199.47 million with net debt to EBITDA at -0.04. When we switch over and look at the enterprise to sales, we see a ratio of 32.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.71.
Conclusion
In conclusion, IGM Biosciences Inc (IGMS) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
